The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 11.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 11.
Number 5: Poster presentations at last week’s European Society for Medical Oncology conference included the results of 5 studies on biosimilar trastuzumab candidates.
Number 4: Sandoz announced that the FDA has accepted its Biologics License Application for a proposed rituximab biosimilar.
Number 3: During a panel at the 2017 AAM Biosimilars Council Conference, regulatory leaders from Pfizer and Sandoz shared their experiences with the development of their biosimilar products.
Number 2: Dr Kashyap Patel, managing partner at Carolina Blood and Cancer Care, addresses challenges surrounding biosimilars in the US marketplace.
Number 1: This week, the FDA approved ABP 215, the first bevacizumab biosimilar.
Finally, last week, our newsletter asked you how important it is to educate patients about biosimilar treatments. To view results of the poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.